Longer-term study of PF-07868489 in pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This study gives the investigational medicine PF-07868489 to people with pulmonary arterial hypertension who have already taken it in a previous Pfizer study. It checks if the medicine continues to be safe and helpful over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You took part in a previous study with the medicine PF-07868489 and finished all of its treatments and tests
- You did not have worsening of your pulmonary arterial hypertension that required a hospital stay during that previous study
- You are not waiting for a lung or heart-lung transplant, and you don't have planned surgery for your lung condition
- You do not have a liver-related lung problem called hepato-pulmonary syndrome
- You are not taking GLP-1 agonist medicines (like Ozempic, Wegovy, or Mounjaro)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe pulmonary hypertension–targeted medicines (and some calcium-blocking medicines) are over time. It uses a computer system to follow you after diagnosis, looking at outcomes and side effects.
This observational study is looking at people diagnosed with pulmonary hypertension to better understand how it behaves over time. You may help researchers by allowing repeated check-ins for years and sharing symptom and test information.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.